Abstracts tagged "safety and women’s health"

Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Sonia Panchal¹, Julia Flint², Maud van de Venne³, Madeline Piper⁴, Alice Hurrel⁵, Joel Cunningham⁵, Mary Gayed⁶, Karen Schreiber⁷, Subha Anthanari⁸, Mohamed Nisar⁸, David Williams⁹, Munther Khamashta¹⁰, Caroline Gordon¹¹ and Ian Giles², ¹Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ²UCL Division of Medicine, University College London, London, United Kingdom, ³Obstetrics and Gynaecology, North Bristol NHS Trust, Bristol, United Kingdom, ⁴Ysbyty Ystrad Fawr, Aneurin Bevan Health Board Wales, Wales, United Kingdom, ⁵Institute for Women's Health, University College London, London, United Kingdom, ⁶Rheumatology Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom, ⁷Lupus Research Unit, Division of Infection and Immunity, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰Lupus Research Unit, Division of Women's Health, Guy's and St Thomas' NSH Foundation Trust, London, United Kingdom, ¹¹Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].